COMMUNIQUÉS West-GlobeNewswire

Hapbee Technologies Teams Up with Liberty Alliance to Deliver Wearable Sleep and Performance Technology to the Defense Sector; Updates Status of Audited Financial Statements
15/05/2025
VANCOUVER, British Columbia, May 15, 2025 (GLOBE NEWSWIRE) -- Hapbee Technologies, Inc. (TSXV: HAPB | OTCQB: HAPBF), a leading provider of wearable wellness technology, is proud to announce it has teamed up with Liberty [...]
Globus Medical Announces $500 Million Share Repurchase Program
15/05/2025
AUDUBON, Pa., May 15, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced that its Board of Directors has authorized a share repurchase program of up [...]
60 Degrees Pharmaceuticals Announces First Quarter 2025 Results
15/05/2025
Q1 2024 net product revenues increased 55% year-over-year to $163.6 thousand. Gross profit increased 124% to $90.3 thousand. WASHINGTON, May 15, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP ; [...]
Rakovina Therapeutics Announces Strategic Private Placement, Convertible Debt Financing, and Share Consolidation to Accelerate US-Focused Growth and AI-Powered Oncology Innovation
15/05/2025
$3 Million Lead Order from Strategic Investors Supports Bold Transformation VANCOUVER, British Columbia, May 15, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO) (“ Rakovina ” or the “ Company [...]
Shuttle Pharma Provides Corporate Update
15/05/2025
GAITHERSBURG, Md., May 15, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty pharmaceutical company focused [...]
Biofrontera Inc. Reports First Quarter 2025 Financial Results and Provides a Business Update
15/05/2025
Conference call begins at 10:00 a.m. Eastern time on Friday, May 16, 2025 WOBURN, Mass., May 15, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company specializing in the [...]
BioSyent Declares Second Quarter 2025 Dividend
15/05/2025
MISSISSAUGA, Ontario, May 15, 2025 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its Board of Directors has declared a quarterly dividend of $0.05 per common [...]
BioSyent Releases Financial Results for First Quarter 2025
15/05/2025
MISSISSAUGA, Ontario, May 15, 2025 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the first quarter (Q1) ended March 31, 2025. Key highlights include: (CAD) Q1 [...]
Moody's Investor Services Upgrades Teva Amid Continued Success of Pivot to Growth Strategy
16/05/2025
TEL AVIV, Israel, May 15, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals (NYSE and TASE: TEVA) today announced that Moody's Investor Services (“Moody's”) has raised the company's corporate credit rating to Ba1, outlook [...]
HCW Biologics Reports First Quarter 2025 Business Highlights and Financial Results
16/05/2025
MIRAMAR, Fla., May 15, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel [...]
FuturHealth Under Review: Best GLP-1 Semaglutide Medication Prescription for Weight Loss with No Insurance
16/05/2025
Discover How FuturHealth’s Affordable Semaglutide Subscription Program Helps Users Lose Weight Without Insurance, Prescriptions, or Hassle—A Game-Changer in the GLP-1 Weight Loss Revolution San Diego, May 15, 2025 ( [...]
Ancient Biblical Remedies Under Review: Ancient Lost Remedies Revived with Hidden Healing Secret Remedies of the Scriptures
16/05/2025
365 Daily Health Unveils “The Encyclopedia of Natural Remedies” — A Faith-Based Digital Guide Reviving Ancient Biblical Remedies with Over 100 Scripture-Inspired Healing Practices for Holistic Wellness, Spiritual [...]
Biofrontera Inc. Announces New Patent Protection on Ameluz® until 2043 and the Completion of Patient Enrollment in Phase 2b Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% for the Treatment of Moderate to Severe Acne Vulgaris
15/05/2025
Biofrontera has received patent approval for the revised formulation of Ameluz ® , which extends patent protection through to December 2043 Ameluz PDT offers the potential for effective treatment of moderate to severe [...]
Sanofi: Informations relatives au nombre de droits de vote et d'actions - Avril 2025
15/05/2025
Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L. 233-8 II du Code de commerce et l’article 223-16 du Règlement général de l’Autorité des Marchés Financiers Sanofi Société [...]
Sanofi: Information concerning the total number of voting rights and shares - April 2025
15/05/2025
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’ [...]
Regeneron Prevails over Amgen in Antitrust PCSK9 Lawsuit Protecting Biotech Innovation and Patient Access to Life-Saving Treatments
15/05/2025
Federal court jury found Amgen liable for violating antitrust and tort laws by using cross-therapeutic bundled rebates to prevent Praluent ® (alirocumab) from competing in the market Jury awarded Regeneron $135.6 [...]
Arialief Criticism Reviewed: The Tainted Neuropathy Relief Controversy Published
15/05/2025
Unmasking the Truth About Arialief: Honest Reviews, Ingredient Warnings, and the Real Reasons Behind User Complaints In This Arialief Review, You’ll Discover: What Arialief is and how Arialief is marketed as a top [...]
RETRANSMISSION – Cosmos Health Reports Q1 2025 Results: Adjusted Profitability Achieved as Gross Profit Rises 54% to $2.05M; Operating Cash Burn Down 95%, or $3.2M, to $0.19M; Approaching Cash Flow Breakeven
15/05/2025
CHICAGO, May 15, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of [...]
Philips successfully prices offering of Notes for EUR 1 billion to be used for repayment of existing debt and to finance eligible green projects
15/05/2025
May 15, 2025 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the successful pricing of its offering of EUR 500 million fixed rate notes due 2030 [...]

Pages